High materiality7/10
Abivax initiated with a Buy at Goldman Sachs
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Source-backed market context you can read and share without an account.
bullish
What happened, with direct paths to the underlying reporting
Goldman Sachs initiates coverage on ABVX with a Buy rating; target $155; current price $119.46.
Target: $155
Posted price: $119.46
Analyst firm: Goldman Sachs
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.